Announcement

14 Aug 2017

The Centre for Drug Development is pleased to announce the successful conclusion of its tender for biomarker delivery for early phase clinical trial work.

The tender included both novel assay development and sample processing. The tender was the first of its kind to be issued to the ECMC network. Positive responses from across the network at the expression of interest stage indicated a strong willingness to consider a new way of working within academia.

14 Aug 2017

Following on from the success of the first workshop in London earlier this year, CRUK’s Centre for Drug Development (CDD), in collaboration with the ECMC Programme Office, hosted a second workshop, ‘Delivery of Early Phase Trials: How can we excel?’, in Newcastle on 22 June 2017.

14 Aug 2017

Pre-announcement: Newcastle University is seeking to recruit a new Clinical Chair in Molecular Pathology. This exciting opportunity will be advertised in September 2017. We will be looking for a talented and highly motivated individual to spearhead our programme in Molecular Pathology, working closely with the Newcastle EPSRC/MRC Molecular Pathology Node (www.newcastlepathnode.org.uk) one of six awarded across the UK.

14 Aug 2017

From September 2017, the ECMC Patient and Public Involvement Group will be offering a new advisory service to the ECMC network. If your ECMC does not currently have capacity to undertake an involvement activity in a project, you can come to the ECMC PPI Group for input. This could include:

16 Jun 2017

As part of the new quinquennium, Cardiff ECMC has begun setting up an ECMC Haematology network.

The main purpose of the network is to promote haematology activities within the ECMC, and consider ways in which a collective group can:

· Attract more early-phase haematology trials within the ECMC and share information about them

· Initiate academic early-phase trials (ideas and proposals, joining up infrastructure etc)

16 Jun 2017

The ECMC Translational Science subgroup of QATS (Quality Assurance & Translational Science group) organised its very first conference titled ‘Opportunities and challenges with emerging biomarker technologies and their application in early phase trials’ on 20 March. The one-day event was held at the ICR in Sutton and organised by Karen Swales, Senior Scientific Officer, ICR CRUK Therapeutics Unit and chair of the Translational Science subgroup.

16 Jun 2017

Both the CRUK Stratified Medicine Programme (SMP2) and the National Lung Matrix Trial (NLMT) are at a crucial phase of trial delivery.

SMP2 and NLMT are open to recruitment at 17 and 16 ECMCs respectively. Both study teams are collaborating to set up three new sites (Liverpool, Maidstone and Devon and Exeter) as part of a phased approach that aims to introduce several new sites across the country.

11 Apr 2017

The development of new treatments for pancreatic cancer is set to be transformed by a £10m investment by Cancer Research UK into a network of clinical trials, aiming to find the right trial for the right patient.

11 Apr 2017

The UK’s only current trial dedicated to the treatment of myelomonocytic leukaemia (CMML) has recruited its first patient. The Phase II MONOCLE study has opened at the Institute of Cancer & Genetics at Cardiff University, and has received funding support from the Cardiff ECMC.

Pages